GREEN SESSION: SPY +0.59% | Range-bound
SESSION RECAP
Today's trading session started with a subdued open as the S&P 500 commenced at $686.54, oscillating sideways throughout the day, signaling a consolidative pattern. Initial hesitation was overcome by a mid-morning rally, primarily driven by a strong performance in materials and technology sectors. Notably, the S&P 500 reached an intraday high of $692.32 before settling robustly at $691.81, reflecting a modest gain of 0.59%. The NASDAQ outperformed, fueled by substantial upticks in major tech names, closing at $623.42, marking a significant increase of 0.88%. The Russell 2000 led the charge, ending strongly at $256.06, up by 1.32%, showing increased investor interest in smaller-cap growth.
A broad market rally was evident, with 9 out of 11 sectors posting gains, signifying healthy breadth. Noteworthy was the decline in volatility, as evidenced by the VIX slipping to 14.74, down 1.07%, aligning with a "normal" volatility regime. However, the energy sector faced adverse conditions, leading to a sharp downside correction. Energy stocks like Chevron and Exxon Mobil underperformed amid weakening crude prices, illustrating the day's most significant sectoral rotation.
MARKET SCORECARD
- S&P 500 (SPY): $686.54 (Open) → $691.81 (Close) | +0.59% | Range: $687.78-$692.32 - NASDAQ (QQQ): $623.42 (Close) | +0.88% - Russell 2000 (IWM): $256.06 (Close) | +1.32% - VIX: 14.74 (-1.07%) - Volume: Normal (0.81x average)
TODAY'S WINNERS
- Texas Instruments (TXN): Surged 8.43% to $192.1 on better-than-expected earnings guidance. - Accenture (ACN): Gained 4.53% closing at $275.93, after announcing a strategic acquisition. - Amazon (AMZN): Rallied 3.38% to $240.93 following reports of record holiday season sales. - Salesforce (CRM): Rose 2.59% to $262.9 after an upgrade from a major brokerage. - IBM: Increased by 2.54% reaching $302.47 on news of advancements in quantum computing.
TODAY'S LOSERS
- Chevron (CVX): Declined 4.46% to $156.54 amid a continued drop in crude oil prices. - Tesla (TSLA): Fell 4.14% to $432.96 following a mixed reception to its latest production numbers. - Exxon Mobil (XOM): Dropped 3.44% to $121.05 alongside sectoral weaknesses in energy. - AMD: Down 3.04% to $214.35, partly due to profit-taking after recent strong advances. - Philip Morris (PM): Decreased by 2.94% to $155.16 on weakening tobacco consumption trends.
SECTOR ROTATION ANALYSIS
Today's session was characterized by a noticeable rotation into materials, healthcare, and technology sectors, indicating a preference for growth and innovation-oriented stocks. This sector leadership reflects a moderately bullish risk appetite, with investors embracing sectors tied to economic expansion. In contrast, the lagging performance in energy underscores persistent challenges confronting the sector due to fluctuating commodity prices.
TECHNICAL TAKEAWAYS
- S&P 500 tested resistance around $692, with robust support established at $687. - The NASDAQ broke prior resistance at $620, setting a new floor for potential consolidation. - Russell 2000's close above $255 signals potential breakout continuation toward $260. - VIX hovering below 15 suggests a stable volatility environment conducive to steady market trends.
LOOKING AHEAD
Traders should keep an eye on overnight developments, particularly in energy commodities which could impact tomorrow's sentiment. Futures during Asian and European sessions will be critical in gauging the global risk appetite. Key economic releases include the ADP employment change, offering early indications ahead of Friday's jobs report.
SESSION VERDICT
Today's session was an "Accumulation session as buyers stepped in at support," with broad sector participation and optimism surrounding growth-oriented stocks.
This edition was published to members after the close on Tuesday, January 06, 2026.
Get every edition the moment it's released — plus the model portfolio and regime dashboard.
Archived market commentary from Assets Bulletin, an independent financial publication. Informational only — not investment advice.